Grand Hopital De Charleroi

The Grand Hopital De Charleroi conducts extensive research on solid tumors and hematologic malignancies, aiming to evaluate new therapeutic agents and improve patient survival.

• Targeted therapies for HER2‑positive and HER2‑low breast cancer
• Immunotherapy combinations for non‑small cell lung cancer
• Novel antibody‑drug conjugates in advanced ovarian and pancreatic cancers
• Precision medicine approaches for colorectal and gastric cancers

With 156 active trials and 54 investigators, the site is a leading hub for oncology innovation in Belgium.

Clinical studies at the hospital focus on leukemia and lymphoma, testing cutting‑edge agents to enhance remission rates and quality of life.

• CAR‑T and bispecific antibodies for acute lymphoblastic leukemia
• Novel proteasome inhibitors in multiple myeloma maintenance
• Combination regimens for diffuse large B‑cell lymphoma in older adults
• Stem cell transplantation strategies for peripheral T‑cell lymphoma

The department’s expertise supports a broad portfolio of hematologic trials, reflecting the site’s commitment to blood‑cancer research.

Researchers investigate innovative approaches to reduce cardiovascular risk, especially in patients with established atherosclerotic disease.

• RNA‑based therapies to lower lipoprotein(a) levels
• Small‑molecule inhibitors targeting inflammatory pathways
• Long‑acting agents for secondary prevention of myocardial infarction and stroke

The cardiovascular program leverages the site’s multidisciplinary team to advance preventive cardiology.

The center runs trials aimed at improving outcomes for patients with lung cancer and other serious respiratory conditions.

• EGFR and ALK inhibitor combinations for advanced non‑small cell lung cancer
• Immunotherapy with checkpoint inhibitors in small cell lung cancer
• Radiation‑plus‑immunotherapy strategies for early‑stage NSCLC after surgery

These studies address both targeted and immune‑based treatments, reflecting a comprehensive lung‑cancer research agenda.

Clinical trials target gastrointestinal malignancies, evaluating novel agents to increase response rates and prolong survival.

• FGFR‑targeted therapies for gastric and gastroesophageal junction cancers
• PARP inhibitor combinations in BRCA‑mutated colorectal cancer
• Anti‑angiogenic agents for metastatic colorectal adenocarcinoma
• Adaptive radiation approaches for locally advanced rectal cancer

The site’s gastro‑oncology team collaborates closely with surgical and radiotherapy units to deliver integrated trial designs.

Research includes both inflammatory skin disorders and dermatologic manifestations of systemic disease, focusing on new biologic and small‑molecule therapies.

• IL‑17 and IL‑23 pathway inhibitors for atopic dermatitis
• Adjustable dosing studies of brodalumab in severe plaque psoriasis
• Targeted treatments for hidradenitis suppurativa

These trials aim to improve symptom control and long‑term skin health for diverse patient populations.

The hospital conducts investigations into therapies for chronic infections and opportunistic fungal diseases, seeking safer and more effective options.

• Antiviral strategies for chronic hepatitis B
• Novel antifungal agents against multidrug‑resistant molds
• Antibiotic stewardship trials for febrile neutropenia in hematology patients

By integrating infectious disease expertise with oncology care, the site addresses critical complications in immunocompromised patients.